Your session is about to expire
← Back to Search
Folfirinox + SBRT for Pancreatic Cancer (BCC-RAD-13 Trial)
BCC-RAD-13 Trial Summary
This trial is testing a new combination of two cancer treatments to see if it is safe and effective for pancreatic cancer.
BCC-RAD-13 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBCC-RAD-13 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 528 Patients • NCT03504423BCC-RAD-13 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with pancreatic cancer.I have had cancer in the past 3 years.I am 18 years old or older.I have liver problems causing jaundice or blood clotting issues.I have received treatment for pancreatic cancer before.I am fully active or can carry out light work.My cancer has spread to other parts of my body, as confirmed by a team of doctors.Your recent blood tests show that you have enough healthy blood cells and your organs are functioning properly. You need to agree to take part in the study.I have AIDS as defined by the CDC, but haven't been tested for HIV for this study.
- Group 1: Folririnox with SBRT
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many volunteers are engaged in this clinical research?
"Affirmative. Clinicaltrials.gov registers that this clinical trial is currently recruiting new patients, which was first published on the 1st of May 2014 and most recently edited on October 24th 2019. The study requires 28 participants from a single medical centre to participate in it."
To what maladies does Folfirinox typically provide relief?
"Folfirinox has been commonly used to manage rectal carcinoma; however, it can also benefit patients dealing with colorectal carcinoma, ovarian cancer and sarcoma."
Is there presently an opportunity to join this clinical trial?
"Affirmative. This trial is currently gathering participants, as per the information found on clinicaltrials.gov; it was initially listed on May 1st 2014 and its most recent alterations were made October 24th 2019. To complete this medical experiment, 28 individuals must be enrolled at one location."
Has Folfirinox been sanctioned by the FDA?
"The safety of Folfirinox stands at a score 2 on the 1 to 3 scale. This is because, while there is evidence that it may be safe for use, no data has been collected yet which shows its efficacy."
Have previous investigations utilized Folfirinox for research purposes?
"Currently, there are 643 investigations involving Folfirinox underway with 201 of them being in Phase 3. The trials for this drug have been set up across 27,590 locations, including Guangzhou and Guangdong."
Share this study with friends
Copy Link
Messenger